Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors

Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR. We have recently identified cyclin-dependent kinase 5 (Cdk5) as novel alternat...

Descripción completa

Detalles Bibliográficos
Autores principales: Weitensteiner, Sabine B., Liebl, Johanna, Krystof, Vladimir, Havlíček, Libor, Gucký, Tomáš, Strnad, Miroslav, Fürst, Robert, Vollmar, Angelika M., Zahler, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545992/
https://www.ncbi.nlm.nih.gov/pubmed/23336010
http://dx.doi.org/10.1371/journal.pone.0054607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545992/
https://www.ncbi.nlm.nih.gov/pubmed/23336010
http://dx.doi.org/10.1371/journal.pone.0054607

Ejemplares similares